資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/32540
|
| 標題: | The efficacy and safety of ceftaroline in the treatment of acute bacterial infection in pediatric patients - a systemic review and meta-analysis of randomized controlled trials |
| 作者: | Chih-Wei Chen(陳志偉)
Chang, Shen-Peng
Huang, Hui-Ting
Tang, Hung-Jen
Lai, Chih-Cheng |
| 貢獻者: | Chi Mei Med Ctr, Div Neurosurg, Dept Surg
Chia Nan Univ Pharm & Sci, Dept Occupat Safety & Hlth, Inst Ind Safety & Disaster Prevent, Coll Sustainable Environm
Chi Mei Med Ctr, Dept Pharm
China Med Univ, Sch Pharm
Chi Mei Med Ctr, Dept Med
Chi Mei Med Ctr, Dept Intens Care Med |
| 關鍵字: | ceftaroline
acute bacterial infection
pediatric
community-acquired pneumonia
skin and skin structure infection |
| 日期: | 2019 |
| 上傳時間: | 2020-07-29 13:49:06 (UTC+8) |
| 出版者: | DOVE MEDICAL PRESS LTD |
| 摘要: | Objectives: This meta-analysis aims to assess the clinical efficacy and safety of ceftaroline in treating acute bacterial infections - community-acquired pneumonia (CAP) and skin and skin structure infection (SSSI) in pediatric patients. Methods: The Pubmed, Embase, ClinicalTrials. gov. and the Cochrane databases were searched up to December 31, 2018. Only randomized controlled trials (RCTs) evaluating ceftaroline and other comparators in the treatment of acute bacterial infection in pediatric patients were included. The primary outcome was the clinical cure rate and the secondary outcome was the risk of adverse event. Results: Three RCTs were included. Overall, ceftaroline had a clinical cure rate at end of therapy (EOT) and test of cure (TOC) similar to comparators in the treatment of acute bacterial infection (at EOT, OR, 1.93; 95% CI, 0.88-4.25, I-2= 0%, and at TOC, OR, 1.36; 95% CI, 0.64-2.91, I-2= 14%). In addition, ceftaroline had a clinical failure rate at EOT and TOC similar to comparators in the treatment of acute bacterial infection (at EOT, OR, 0.62; 95% CI, 0.22-1.76, I-2= 0%, and at TOC, OR, 0.68; 95% CI, 0.24-1.91, I-2= 0%). No significant differences were found for the risk of treatment-emergent adverse events (TEAE) in all and different degrees between ceftaroline and comparators (OR, 0.81; 95% CI, 0.37-1.78, I2= 56%). The risks of TEAE and severe adverse events related to study drug were similar between ceftaroline and comparators (TEAE related to study drug, OR, 0.98; 95% CI, 0.52-1.82, I-2= 0%, severe adverse event related to study drug, OR, 1.09; 95% CI, 0.22-5.44, I2= 22%). Conclusions: The clinical efficacy of ceftaroline is as good as comparator therapy in the treatment of acute bacterial infections - CAP and SSSI, and this antibiotic is well tolerated as the comparators. |
| 關聯: | Infection and Drug Resistance, v.12, 1303-1310 |
| 顯示於類別: | [職業安全衛生系(含防災所)] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| 10.2147-IDR.S199978.pdf | | 1560Kb | Adobe PDF | 366 | 檢視/開啟 | | index.html | | 0Kb | HTML | 1135 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
